相关临床试验
8
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1967
已完成
5
62.5%
招募中
3
37.5%
暂无批准数据
- A 12-month La Trobe University study found 78% of participants using the Defeat Diabetes digital program improved blood glucose levels, with 18% achieving remission without glucose-lowering medication. - Among those on diabetes medication at baseline, 13% discontinued all diabetes drugs, 10% ceased blood pressure medication, and 7% stopped cholesterol-lowering medication by 12 months. - Participants lost an average of 5 kg, with significant improvements in liver markers (ALT and GGT), well-being scores, and diabetes-related distress. - The study, published in Diabetes Research and Clinical Practice, is the longest real-world trial of a digitally delivered low-carbohydrate nutrition program in Australia.
- BioNTech has installed two modular BioNTainer units at its Bundoora facility in Melbourne, making Victoria one of only two locations globally with this technology. - The facility is expected to support up to 1,200 jobs across the broader biotechnology industry over the next decade. - The BioNTainers will enable small-scale manufacturing for R&D, allowing researchers and biotech companies to collaborate on cancer therapies and vaccines for emerging diseases. - The installation, located within La Trobe University's $5 billion University City precinct, strengthens Victoria's position as a leading mRNA ecosystem alongside Moderna's existing presence.
- Taiwanese researchers from NTHU and NHRI have developed a breakthrough small-molecule drug that treats chronic intestinal inflammation by blocking PANX1 ion channels in intestinal cells. - The new drug addresses a significant medical need, with IBD affecting 5% of Western populations and showing increasing prevalence in Taiwan, where ulcerative colitis affects 19.6 per 100,000 people. - The research team successfully modified the drug's molecular structure to eliminate previous liver toxicity issues while enhancing its efficacy, potentially extending its application to other inflammatory conditions.
- Researchers have discovered WD34, a novel antibody-like molecule, that inhibits malaria parasite infection at various disease stages. - WD34 binds to the AMA1 protein, common across malaria species, blocking the mechanism parasites use to enter liver and red blood cells. - Pre-clinical trials suggest WD34 could protect against multiple malaria parasite species, offering a potential broad-spectrum therapeutic option. - The discovery opens new avenues for developing a universal malaria vaccine, addressing drug resistance and treatment failures.
